---
title: "Obefazimod (ABX464) in Ulcerative colitis: Access and distribution"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: Access and distribution. Topics: Commercial organization: market access, pricing, and patient services leadership appointed in July 2026; Commercial preparation for a U.S. launch; Distribution and channel strategy under board review; Commercial supply: outsourced manufacturing and a second source manufacturer. 4 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description/access-and-distribution"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: Access and distribution

<a id="heading-2.1.2.11"></a>

## 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

### Commercial organization: market access, pricing, and patient services leadership appointed in July 2026

> “today announced the expansion of its Commercial Leadership Team with four strategic appointments spanning marketing, patient services, sales, commercial operations, and market access.”
> “As Global Head of Patient Services at Abivax, he leads the development of the Company's patient services model for obefazimod.”
> “As Global Head of Market Access & Pricing, he is responsible for developing market access and pricing strategies to support the potential commercialization of obefazimod.”

Source: [Abivax press release, commercial leadership appointments (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-strengthens-commercial-capabilities-strategic-leadership)

<a id="topic-2.1.2.11-2"></a>

### Commercial preparation for a U.S. launch

> “The increase was driven by costs related to the Company’s continued preparation for potential future sales and commercialization efforts for obefazimod in the U.S. which are expected to continue to accelerate in preparation for commercial launch.”

Source: [Abivax first half 2026 results announcement (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-presents-business-updates-and-first-half-2026-financial)

<a id="topic-2.1.2.11-3"></a>

### Distribution and channel strategy under board review

> “Review and advise on launch readiness and execution plans, including market positioning, market access, pricing and reimbursement, distribution and channel strategy, patient services, commercial infrastructure, and sales and marketing;”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="topic-2.1.2.11-4"></a>

### Commercial supply: outsourced manufacturing and a second source manufacturer

> “We outsource all manufacturing operations and rely on European and North American third-party CMOs to supply clinical trials and finalize the development of obefazimod.”
> “We are in the process of further optimizing and scaling up our supply chain for obefazimod to ensure capacity for our expected commercial supply, if the FDA or foreign regulatory authority approved.”
> “In addition, we are in process of establishing a second source manufacturer for obefazimod to ensure continuity of product supply.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="topic-2.1.2.11-5"></a>

### Specialty pharmacy network and patient support program

No evidence found.

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
